Neuropathic pain is a frequent feature of peripheral neuropathy adversely impacting patients’ quality of life and increasing health care costs. The PROPANE STUDY aims to address these issues through a solid clinical and genetic approach employing an innovative technological platform.
The main objectives are to resolve the genetic architecture of painful neuropathy achieving a stratification of high-risk neuropathic pain patients by novel biomarkers, to deepen understanding of underlying mechanisms and druggable targets and to identify new molecules tailored to potentially drug-responder patients and determine their effects in pre-clinical settings.
Consortium: 9 partners from 6 countries
Coordinator of the project: Fondazione IRCCS Istituto Neurologico Carlo Besta – Italy
Funding programme: FP7-HEALTH
Project start: October 2013
End date for the project: 30 September 2016
For more information go to the website www.propanestudy.eu